AEMPS Bulletin November 2022 on medicinal products for human use

AEMPS

Source: actasanitaria.com

This report outlines the medicines already assessed by the Spanish Agency for Medicines and Health Products (AEMPS), which are considered to be of greatest interest to healthcare professionals. These are positive technical opinions from this national regulatory body prior to the authorisation and placing on the market of the medicinal product, which will take place in a few months’ time.

Epigraph	Basic information Data Protection
Responsable	DISTEFAR DEL SUR, S.L.
Purpose	Process your inquiry / request Detailed information on Data Protection
Legitimation	Consent Detailed information on Data Protection
Recipients	It is not expected to carry out data communications to third parties, except legal obligation Transfers of data to third countries outside the European Union will not be carried out Detailed information on Data Protection
Rights	You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection
Additional Information	You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

CENTRAL

MADRID DELEGATION

Links of interest

AEMPS Bulletin November 2022 on medicinal products for human use

Related entries

Health sector awaits upcoming regulatory changes: ‘It’s a critical time’.

Europe streamlines access to clinical trial information

Patient safety, a pharmaceutical industry commitment throughout the life of a medicine